表皮生長因子受體拮抗劑相關(guān)皮膚不良反應(yīng)表現(xiàn)及治療進(jìn)展
發(fā)布時間:2018-07-24 10:14
【摘要】:近十幾年來,除了手術(shù)、化療、放療三項常規(guī)治療手段之外,分子靶向藥物使腫瘤治療有了重大突破。分子靶向藥物治療作為一種新型治療手段,正在腫瘤內(nèi)科治療領(lǐng)域發(fā)揮越來越重要的作用。其中,表皮生長因子受體拮抗劑(epidermal growth factor receptor inhibitors,EGFRIs)是目前臨床應(yīng)用最為廣泛的一類分子靶向藥物。EGFRIs的主要不良反應(yīng)為皮膚不良反應(yīng)、腹瀉、乏力、間質(zhì)性肺炎等。皮膚不良反應(yīng)是EGFRIs最常見的不良反應(yīng),經(jīng)常會影響患者生存質(zhì)量,導(dǎo)致藥物減量或停藥。其主要表現(xiàn)為痤瘡樣皮疹甚至膿皰樣丘疹、皮膚瘙癢、皮膚干燥、甲溝炎及甲裂、毛發(fā)改變及超敏反應(yīng)。目前,臨床上標(biāo)準(zhǔn)治療方案包括抗生素、糖皮質(zhì)激素、抗組胺藥等,但是療效并不滿意。本文旨在對EGFRIs相關(guān)皮膚不良反應(yīng)表現(xiàn)及治療進(jìn)展進(jìn)行綜述,以期為臨床提供參考。
[Abstract]:In recent years, in addition to surgery, chemotherapy and radiotherapy, molecular targeted drugs have made a major breakthrough in tumor treatment. As a new therapeutic method, molecular targeted drug therapy is playing a more and more important role in the field of oncology. Among them, epidermal growth factor receptor antagonist (epidermal growth factor receptor inhibitors (EGFRIs) is one of the most widely used molecular targeting drugs. The main adverse reactions of EGFRIs are skin adverse reactions, diarrhea, fatigue, interstitial pneumonia and so on. Skin adverse reactions are the most common adverse reactions in EGFRIs, which often affect the quality of life of patients and lead to drug reduction or withdrawal. Its main manifestations are acne like rash and even pustular papules, pruritus, dry skin, thyroiditis and nail cleavage, hair change and hypersensitivity. At present, the standard therapy includes antibiotics, glucocorticoids and antihistamines, but the effect is not satisfactory. The purpose of this article is to review the clinical manifestation and treatment progress of EGFRIs related skin adverse reactions in order to provide reference for clinical practice.
【作者單位】: 北京中醫(yī)藥大學(xué)中日友好臨床醫(yī)學(xué)院;中日友好醫(yī)院中西醫(yī)結(jié)合腫瘤科;
【基金】:北京市科委首都特色應(yīng)用研究項目(編號:Z151100004015168)資助~~
【分類號】:R730.5
[Abstract]:In recent years, in addition to surgery, chemotherapy and radiotherapy, molecular targeted drugs have made a major breakthrough in tumor treatment. As a new therapeutic method, molecular targeted drug therapy is playing a more and more important role in the field of oncology. Among them, epidermal growth factor receptor antagonist (epidermal growth factor receptor inhibitors (EGFRIs) is one of the most widely used molecular targeting drugs. The main adverse reactions of EGFRIs are skin adverse reactions, diarrhea, fatigue, interstitial pneumonia and so on. Skin adverse reactions are the most common adverse reactions in EGFRIs, which often affect the quality of life of patients and lead to drug reduction or withdrawal. Its main manifestations are acne like rash and even pustular papules, pruritus, dry skin, thyroiditis and nail cleavage, hair change and hypersensitivity. At present, the standard therapy includes antibiotics, glucocorticoids and antihistamines, but the effect is not satisfactory. The purpose of this article is to review the clinical manifestation and treatment progress of EGFRIs related skin adverse reactions in order to provide reference for clinical practice.
【作者單位】: 北京中醫(yī)藥大學(xué)中日友好臨床醫(yī)學(xué)院;中日友好醫(yī)院中西醫(yī)結(jié)合腫瘤科;
【基金】:北京市科委首都特色應(yīng)用研究項目(編號:Z151100004015168)資助~~
【分類號】:R730.5
【參考文獻(xiàn)】
相關(guān)期刊論文 前8條
1 王學(xué)謙;張英;劉杰;劉志艷;石紅;鄭佳彬;林洪生;;自擬皮疹顆粒治療EGFR-TKI相關(guān)皮疹的隨機(jī)對照研究[J];世界中西醫(yī)結(jié)合雜志;2016年12期
2 郭慧茹;孫建立;阮廣欣;單孟俊;沈麗萍;;養(yǎng)陰清熱解毒法治療肺癌患者EGFR-TKIs相關(guān)皮疹的臨床研究[J];遼寧中醫(yī)雜志;2016年05期
3 陳學(xué)武;姜靖雯;林海峰;;五味消毒飲治療肺癌患者表皮生長因子受體酪氨酸激酶抑制劑相關(guān)皮疹30例臨床觀察[J];中醫(yī)雜志;2016年10期
4 凌明珠;宋正波;婁廣媛;古翠萍;石志永;施勛;趙s,
本文編號:2141050
本文鏈接:http://sikaile.net/yixuelunwen/zlx/2141050.html
最近更新
教材專著